<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study evaluated the <z:hpo ids='HP_0011009'>acute</z:hpo> toxicity of trimetrexate (TMTX) used in combination with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CsA) for prevention of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) in patients undergoing allogeneic marrow transplantation from HLA-mismatched, related donors </plain></SENT>
<SENT sid="1" pm="."><plain>TMTX has a mechanism of action similar to that of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX); however, unlike MTX, TMTX is not primarily dependent on renal excretion </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were conditioned for transplant with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, anti-thymocyte globulin, and total body irradiation </plain></SENT>
<SENT sid="3" pm="."><plain>TMTX, 10 mg/m2 i.v., was administered on days 1, 3, 6, 11, 18, 25, 32, and 39 after transplant </plain></SENT>
<SENT sid="4" pm="."><plain>CsA, 1.5 mg/kg i.v., was administered every 12 hr beginning on day-1 </plain></SENT>
<SENT sid="5" pm="."><plain>Eleven patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> or <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (median age = 34 yr) received TMTX </plain></SENT>
<SENT sid="6" pm="."><plain>Toxicity assessed included <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>, time to myeloid and platelet engraftment, mucositis, and hepatic and <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Toxicity of TMTX was not different from that observed with MTX in a similar patient population </plain></SENT>
<SENT sid="8" pm="."><plain>One patient died on day 16 before engraftment </plain></SENT>
<SENT sid="9" pm="."><plain>The other 10 patients <z:hpo ids='HP_0000001'>all</z:hpo> engrafted and <z:hpo ids='HP_0000001'>all</z:hpo> developed <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD at a median time of 11 days after transplant </plain></SENT>
<SENT sid="10" pm="."><plain>The major manifestation of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was in the skin, and <z:hpo ids='HP_0000001'>all</z:hpo> but one patient responded to primary therapy with <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Seven patients have survived a median of 447 days after transplant </plain></SENT>
<SENT sid="12" pm="."><plain>No significant toxicity from TMTX was observed </plain></SENT>
<SENT sid="13" pm="."><plain>Further trials are warranted to define the role of TMTX in marrow transplantation </plain></SENT>
</text></document>